Brief: Curevac Q1 Revenue Eur 900 Thousand
20/05/2025 12:04
May 20 (Reuters) - CUREVAC NV 5CV.DE: Q1 REVENUE EUR 900 THOUSAND Q1 PRETAX PROFIT EUR -51.7 MILLION Q1 EBIT EUR -54.7 MILLION STRONG CASH AND CASH EQUIVALENTS POSITION OF EUR 438.3 MILLION AS OF MARCH 31, 2025 REAFFIRMING EXPECTED CASH RUNWAY INTO 2028 YEAR-ON-YEAR DECREASE IN REVENUES WAS PRIMARILY DRIVEN BY LOWER REVENUES FROM GSK FOLLOWING RESTRUCTURING OF PARTNERSHIP IN JULY 2024 FROM A COLLABORATION INTO A LICENCE AGREEMENT AS WELL AS LOWER SALES TO CRISPR THERAPEUTICS NET FINANCIAL RESULT FOR Q1 OF 2025 AMOUNTED TO EUR 3.0 MILLION Source text: ID:nEQ75HTCZa Further company coverage: 5CV.DE (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028